London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Says it all
"With our this simple, 5-minute, painless intervention our Steriwave treatment makes a life-saving impact - in this case, 468 spine surgery patients saved from potentially lethal infections - more than enough to fill a 747 plane. We are truly grateful to Professor Street and the research staff at VGH for their pursuit of better patient outcomes. Postoperative spine infection can be a devastating and expensive complication after spine surgery, with patients at high risk for chronic pain, paralysis, return to the operating room, poor long-term outcomes, and even death. This study conclusively demonstrates that Steriwave is setting a new standard for safety and performance in infection control."
**END**
Another great study completed this will rocket, time to buy in before you miss the rise! This procedure will go world wide in the next year and become common place in spinal surgery.
GLA
9.6-9.975
very small margin
Expecting a JUMP
when next good news
arrives
dyor - imho
Hasbeen
Has been short listed
This is good news
International recognition
is very important
Move on then mate.
Peter
imho - dyor,
The market drop recently is very telling
I have and i do not buy into this yet.
funding/ potential; dilution a big drag on this.
EU,Mexico and Canada moving very slowly and approvals were in last year.
Bucked the market trend again -the dumbtit traders strike again.
Ondine Biomedical’s nasal photodisinfection named as leading photonics biomedical technology for its potential to safely combat AMR
November 13, 2023 02:18 PM Eastern Standard Time
VANCOUVER, British Columbia--(BUSINESS WIRE)--Ondine Biomedical’s Steriwave nasal photodisinfection technology has been shortlisted in the biomedical category of the 2024 international society for optics and photonics SPIE Prism Awards. Ondine’s nasal photodisinfection technology, which has been significantly reducing hospital acquired infections, uses a combination of a photosensitive agent and red laser light to eliminate bacteria, viruses, and fungi in the nose in minutes without generating resistance.
Nasal photodisinfection is a painless, five-minute treatment that uses a patented photosensitive agent and specific, non-UV light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses.
Ondine CEO, Carolyn Cross, comments, “It is fantastic to see photodisinfection receiving wider recognition as a technology that will be transformative for the future of healthcare. As the tide of antimicrobial resistance continues to rise, we are fast approaching a reality where a simple infection could be deadly. Our nasal photodisinfection technology represents a new way of combatting infections and, crucially, unlike antibiotics, it does not develop resistance.”
Photodisinfection has been shown to be highly effective against antibiotic-resistant bacteria, including extensively drug-resistant strains, without showing any resistance formation. This makes photodisinfection an exciting prospect for combatting rising rates of antimicrobial resistance (AMR). Antimicrobial resistance (AMR) remains a major public health concern, causing 1.27 million deaths in 2019.i The AMR death rate is projected to rise to 10 million globally by 2050.ii
Nasal photodisinfection is also widely used in hospitals across Canada, as well as in Europe and Mexico, to prevent healthcare-associated infections (HAIs) following surgery. Surgical site infections (SSIs) are the most common of HAIs, and are a huge burden on both healthcare systems and patients, with the estimated cost of a prosthetic hip or knee infection costing up to $100,000.iii
In hospital settings, pre-surgical use of Steriwave has resulted in significant improvement in post-surgical outcomes including lower rates of infection, reduced patient length of stay, fewer readmissions, lower rates of antibiotic prescribing and significant cost savings.iv,v,vi
Other applications for Ondine’s photodisinfection technology include the treatment of chronic rhinosinusitis, decolonization of burns and wounds, and disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia. Ondine has also completed a proof-of-concept study which showed that photodisinfection effectivel
Read the half year report
It looks good in my opinion
Bodes well for getting to breakeven
in 2024 with all great news of more
hospitals coming on line and brand
recognition gaining momentum
surpassing all expectations
imho - dyor
Peter let the funding get out of the way first
It already has approvals from other countries last year but yet too see and contracts of value
Last years interims were very poor
Just bought more @ 9.67p
Am expecting a JUMP
imho - dyor
All indications are that this is a multi-bagger investment opportunity currently below 10p
RBC target is 60p and personally I have no doubt SP will exceed that
imho - dyor
I would like to invest because it looks very promising but the issue is funding and the need to raise before the year end based on cash at 30 June and first half reduction from 31 December.
Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation.
Photodisinfection is an easy-to-use alternative to topical antibiotics and antifungals because it is highly effective against all types of disease-causing pathogens, including MDR and XDR strains.
Ondine has pioneered nasal photodisinfection as a rapid, non-antibiotic method for decolonizing the nose of the pathogens carried by patients that can lead to HAIs. Steriwave uses a proprietary red light-activated agent to eliminate infection-causing bacteria, viruses, and fungi in the nose, a major reservoir of germs[2], without causing resistance. At the Mazankowski Alberta Heart Institute, Steriwave replaced the previous standard of care, the antibiotic mupirocin. Mupirocin is commonly used for nasal decolonization to prevent SSIs, but has poor rates of patient compliance and reported resistance rates as high as 81%.[3]
10.025-10.34p
good time to buy in my opinion
(before more great news makes SP rise)
dyor
10.575-11.195p
my purchase earlier is shown as sell
It is a good time to buy more (before sky-rocket)
imho - dyor
Nova Scotia's largest hospital is the latest to implement Steriwave nasal photodisinfection for use prior to orthopedic surgery Canadian life sciences company Ondine Biomedical's (LON: OBI) Steriwave® nasal photodisinfection for the prevention of healthcare-associated infections (HAIs) is now available in hospitals across Canada. The latest hospital to implement Steriwave for its orthopedic surgery patients is the Queen Elizabeth II Health Sciences Centre in Halifax, affiliated with Dalhousie University and the largest hospital in Nova Scotia, located on Canada's East Coast.
Steriwave is a highly effective method of preventing infections following surgery. This is particularly important due to growing concern about antimicrobial resistance (AMR), as hospitals must adapt their protocols to combat the rapid rise of drug-resistant pathogens
BRIEF: For the six months ended 30 June 2023, Ondine Biomedical Inc revenues increased 63% to C$428K. Net loss decreased 8% to C$7.9M. Revenues reflect Canada segment increase of 49% to C$390K, United States segment increase from C$0K to C$38K. Lower net loss reflects Research and development decrease of 17% to C$2.2M (expense), General and administration decrease of 7% to C$4.7M (expense).
Fundraising
We are confident in our plans to raise capital to fund the key Phase 3 clinical trial, our ongoing commercial expansion plans, and to fund the Company's operating expenses more generally as we seek to attain short-term milestone objectives and prepare to scale further.
The rise of antimicrobial resistance ("AMR") is driving governments and research institutes to seek new solutions to combat antimicrobial-resistant pathogens and help prevent millions of deaths. Because of the demonstration of efficacy against ESKAPE and extremely drug-resistant pathogens of major concern to global health authorities, we are accelerating our pursuit of non-dilutive funding opportunities and numerous AMR-related government initiatives
RBC target of 60p looks quite achievable in 2024
as the good news continues to accumulate
and as I continue to gradually add to my holding
Thats My main concern but another decent RNS should higher the price before they raise any funds. Happy to hold for now at current S.P.
Well If they can manage raising cash better than HZM, I’ll be happy. Mind you that is a very low bar.
Company will be raising cash soon to complete FDA trials and pilots
How much and at what market price is the question
This has been falling for a long time , just look at the chart
Market is pricing in a fund raising , it is public knowledge